You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):重組抗EGFR人源化單克隆抗體注射液完成I期臨牀試驗研究報告
格隆匯 03-31 17:16

格隆匯3月31日丨復星醫藥(600196.SH)公佈,公司控股子公司上海復宏漢霖生物技術股份有限公司(以下簡稱“復宏漢霖”)研製的重組抗EGFR人源化單克隆抗體注射液在評估其治療標準治療耐藥的轉移性或複發性上皮瘤的前瞻性、開放性、劑量爬坡的I期臨牀試驗中顯示了良好的安全性及耐受性,並已於近日完成相關臨牀研究報告。截至2020年2月,集團現階段針對該新藥已投入研發費用人民幣約1.70億元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account